Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 15/20 | 0.40 |
| ▸ | CA2 | P00918 | 15/20 | 0.40 |
| ▸ | CA4 | P22748 | 15/20 | 0.40 |
| ▸ | CA9 | Q16790 | 15/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495109 | 0.95 | TSHR (0.41) | TSHRGLACA1CA2CA4 | |
| SCHEMBL3492306 | 0.94 | TSHR (0.44) | TSHRGLACA1CA2CA4 | |
| SCHEMBL3492703 | 0.91 | CA1 (0.40) | TSHRCA1CA2CA4CA9 | |
| SCHEMBL3493927 | 0.91 | CA1 (0.39) | TSHRCA1CA2CA4CA9 | |
| SCHEMBL8231116 | 0.90 | TSHR (0.43) | TSHRGLACA1CA2CA4 | |
| SCHEMBL3492450 | 0.90 | CA1 (0.41) | CA1CA2CA4CA9 | |
| SCHEMBL3494534 | 0.90 | CA1 (0.36) | TSHRCA1CA2CA4CA9 | |
| SCHEMBL3493791 | 0.89 | CA1 (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL3496458 | 0.88 | CA1 (0.39) | CA1CA2CA4CA9KMT2A | |
| SCHEMBL13340197 | 0.86 | HDAC1 (0.41) | TSHRGLACA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | TSHR 684/4885GLA 2889/4885CA1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.